Sarepta

Elevidys Shipments Restart: Sarepta Shares Rebound in US Market

ByZain

Elevidys shipments have restarted in the U.S., sparking excitement among investors and patients alike. Sarepta Therapeutics, the company behind this muscular gene therapy, saw its shares jump more than 30% before the bell on Tuesday. This news follows a tough period when shipments paused due to the deaths of two teenage boys earlier this year….

Sarepta

Sarepta Shares Drop as FDA Forces Pause on Gene Therapy Trials

ByZain

Sarepta Therapeutics, a biotech company, hit a rough patch. The FDA forced a pause on its gene therapy trials for Elevidys, causing Sarepta shares to drop fast. This news shook the stock market and left investors and patients worried. We know Elevidys treats Duchenne’s muscular dystrophy, a rare muscle disease. The FDA stepped in after…